OrthoPediatrics (NASDAQ: KIDS) issues 2025 outlook, prelim results

Rhea-AI Filing Summary

OrthoPediatrics Corp. furnished an update on its business by issuing a press release with preliminary unaudited net revenue and free cash flow for the fourth quarter and full year ended December 31, 2025. The company also provided management’s projection of 2026 net revenue and offered a related business update. These figures are described as preliminary estimates that remain subject to completion of the audit process and may change, and the company highlights that actual 2025 and 2026 net revenue could differ materially from the estimates and projections. The disclosure emphasizes that these statements are forward-looking and directs readers to previously disclosed risk factors for elements that could cause results to vary.

Insights

Equity research analyst

Company shares preliminary 2025 figures and 2026 revenue outlook.

OrthoPediatrics Corp. has released preliminary, unaudited net revenue and free cash flow for the fourth quarter and full year ended December 31, 2025, along with a management projection for 2026 net revenue. This type of update gives the market an early view of performance and expectations before final audited results are available.

The company clearly states that these numbers are preliminary and subject to completion of the audit process, and that both 2025 results and 2026 net revenue could differ materially from the estimates and projections. It also frames these as forward-looking statements and points to its Form 10-K risk factors for elements that could drive variance, underscoring typical earnings and forecasting uncertainty.

From an analytical perspective, this update is informational rather than structural: it does not describe changes to capital structure or major transactions, but rather provides early financial indications and outlook. Subsequent filings with final audited figures and any updated guidance will give more concrete data for evaluating the company’s trajectory.

0001425450FALSE00014254502023-03-112023-03-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

______________________

Date of Report (Date of earliest event reported): January 12, 2026

OrthoPediatrics Corp.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

001-38242			26-1761833
(Commission File Number)			(I.R.S. Employer Identification Number)

2850 Frontier Drive Warsaw, Indiana			46582
(Address of principal executive offices)			(Zip Code)

Registrant’s telephone number, including area code: (574) 268-6379

Not Applicable

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.00025 par value per share

KIDS

Nasdaq Global Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 under the Securities Act (17 CFR 230.405) or Rule 12b-2 under the Exchange Act (17 CFR 240.12b-2).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ¨

Item 2.02. Results of Operations and Financial Condition.

On January 12, 2026, OrthoPediatrics Corp. (the "Company”) issued a press release announcing its preliminary unaudited net revenue and free cash flow for the fourth quarter and full year ended December 31, 2025, providing management's projection of 2026 net revenue and providing a related business update. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 2.02, including the information incorporated by reference herein from Exhibit 99.1, is furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

The financial information set forth in this Form 8-K reflects the Company's current preliminary net revenue and free cash flow estimates, is subject to the completion of its audit process, and is subject to change. The Company's fourth quarter and full year ended December 31, 2025 results could differ materially from the preliminary estimates provided in this form 8-K. The Company's net revenue for the full year ended December 31, 2026 could also differ materially from the forecasted amounts. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date of this Form 8-K. You should refer to the “Risk Factors” section of the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 5, 2025, as updated and supplemented by our other SEC reports filed from time to time, for a discussion of important factors that may cause our actual results and net revenue to differ materially from those expressed or implied by these forward-looking statements. Given these risks, uncertainties and other factors, many of which are beyond our control, you are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly release the results of any revision or update of the forward-looking statements, except as required by law.

Item 9.01. Financial Statements and Exhibits.

(d)			Exhibits
			Exhibit No.			Description
			99.1			Orthopediatrics Corp. Press release dated January 12, 2026
			104			Cover Page Interactive Data File (embedded within the Inline XBRL document).

* * * * * *

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			OrthoPediatrics Corp.
Date:   January 12, 2026			By:			/s/ Daniel J. Gerritzen
						Daniel J. Gerritzen, General Counsel and Secretary

- 2 -

FAQ

What did OrthoPediatrics Corp. (KIDS) disclose in this 8-K?

OrthoPediatrics Corp. furnished a press release with preliminary unaudited net revenue and free cash flow for the fourth quarter and full year ended December 31, 2025, along with a projection of 2026 net revenue and a related business update.

Which financial metrics did OrthoPediatrics (KIDS) highlight in its update?

The company highlighted preliminary unaudited net revenue and free cash flow for the fourth quarter and full year 2025, and provided management’s projection of 2026 net revenue.

Are OrthoPediatrics’ preliminary 2025 results final?

No. The company states that the preliminary net revenue and free cash flow figures are subject to completion of its audit process and may change, and that actual fourth quarter and full-year 2025 results could differ materially from these estimates.

Did OrthoPediatrics (KIDS) provide an outlook for 2026?

Yes. Management provided a projection of net revenue for the full year ended December 31, 2026, noting that actual net revenue could differ materially from the forecasted amounts.

How does OrthoPediatrics describe the forward-looking nature of this update?

The company characterizes the estimates and projections as forward-looking statements and cautions readers not to place undue reliance on them, referencing its Form 10-K risk factors for a discussion of elements that could cause actual results to differ.

Where can investors find more details on the OrthoPediatrics (KIDS) business update?

More detail is contained in the press release dated January 12, 2026, which is included as Exhibit 99.1 and incorporated by reference into the report.